Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS...
SHE: 002252
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm...
Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS
Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS...
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...
Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment
Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...
Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion
Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has...